The Curative Effect of Acupuncture Therapy Under Artificial Intelligence Combined with Integrated Chinese and Western Medicine for Lung Cancer Patients and The Intervention Effect of Side Effects After Chemotherapy

doi:10.21203/rs.3.rs-2965489/v1

Download PDF

Research Article

The Curative Effect of Acupuncture Therapy Under Artificial Intelligence Combined with Integrated Chinese and Western Medicine for Lung Cancer Patients and The Intervention Effect of Side Effects After Chemotherapy

https://doi.org/10.21203/rs.3.rs-2965489/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Objective:

this work aimed to investigate the clinical efficacy of artificial intelligence-based acupuncture combined with comprehensive drugs in the treatment of lung cancer (LC) and its intervention effect in the side effects after chemotherapy.

Methods:

88 patients with LC confirmed in Affiliated Quanzhou First Hospital of Fujian Medical University were studied. They were randomly divided into two groups: the experimental group (EG-laser acupuncture robot + integrated Chinese and Western medicine program) and the control group (integrated Chinese and Western medicine program), with 44 cases. The therapeutic effects and chemotherapy side effects of the two groups were compared and analyzed.In the EG, the number of patients whose treatment effects were not significantly effective, effective, and ineffective was 2, 33, and 9, and the number of patients whose treatment effects were not significantly effective, effective, and ineffective was 3, 20, and 21, respectively in the controls, P < 0.05. After treatment, the scores of each dimension in the EG and controls were 30.7 ± 11.2 VS 33.9 ± 10.07, 20.08 ± 4.33 VS 24.5 ± 5.11, 8.77 ± 3.31 VS 11.6 ± 2.88, 8.33 ± 3.36 VS 9.36 ± 4.08, 3.22 ± 1.18 VS 5.31 ± 1.27, P <0.05. After treatment, the TCM syndrome scores of the EG and controls were 19.8 ± 6.06 and 23.6 ± 7.33, P < 0.05. After treatment, the number of patients with nausea and vomiting grade 0, I, II, III, and IV in the EG and controls was compared, and the results were 20 VS 7, 18 VS 3, 3 VS 20, 2 VS 10, and 1 VS 4, P < 0.05. After treatment, the PFS score of the EG was 4.87 ± 2.01, and the PFS score in the controls was 7.11 ± 1.68, P < 0.05. After treatment, the measured values of CD3+, CD4+, and CD8+ in the two groups were 56.08 ± 22.3 VS 52.9 ± 21.81, 35.2 ± 12.3 VS 31.3 ± 11.09, and 26.08 ± 7.74 VS 20.7 ± 8.35, P < 0.05. Acupuncture combined with integrated medicine has a high application value in the treatment of LC and the reduction of adverse reactions (AR).

artificial intelligence

integrated Chinese and western medicine program

acupuncture

lung cancer

adverse reactions

curative effect

Primary bronchial LC, referred to as lung cancer (LC), is one of the most common malignant tumors that seriously threaten people’s life safety. According to relevant clinical data statistics, LC has gradually become the largest cancer in China since 2004. Its morbidity and mortality are very high and increasing year by year, and it is also one of the tumors with the longest prognosis [1, 2]. LC has no obvious symptoms in the early stage, so its early diagnosis and treatment are lacking, and more than half of patients are already in stages IIIb and IV at the time of the first diagnosis. At present, the cure rate of modern medical treatment of the disease is low, the median survival is generally less than 6 months, and the 5-year survival rate is only 5–10% [3].

At present, relevant clinical studies have shown that cisplatin as the main body of two-drug combination therapy for patients with better conditions can reduce symptoms and prolong survival, relevant clinical trials and evidence-based medicine results show that the efficacy of systemic chemotherapy is better than supportive care alone. Combination chemotherapy can only increase one-year survival by 10% and is not significant for prolongation of survival [4]. IIIb standard treatment is the most common local treatment, and its general median survival is 11 ~ 13 months. However, it should be noted that patients with PS ≥ 2 had worse treatment outcomes and more intense toxicities compared with patients with PSO ~ 1. Currently, new drugs of clinical concern are gefitinib and erlotinib. Both drugs are EGFR-TKI and both belong to molecularly targeted drugs. Recent results of large-scale clinical studies in China and internationally have shown that oral administration of gefitinib and erlotinib in some non-responders to chemotherapy can control the incidence and control rate of the disease between 35% and 54%, with a median survival of 6 to 8 months [5]. In addition, targeted drugs and anti-vascular drugs, such as Endostar, have also shown good application prospects in the treatment of LC. However, the price of these drugs is generally high, which is the main reason that these drugs can’t be widely promoted in clinical practice [6].

At present, the treatment guidelines for LC still take the comprehensive treatment of western medicine as the main direction of treatment, but many adverse reactions (AR) expose the limitations of western medicine treatment. Many researchers in China try to treat LC using traditional Chinese medicine (TCM) [7, 8]. Some scholars have conducted a meta-analysis of clinical studies on LC treated with TCM alone in the past seven years. The results showed that the treatment of LC with TCM had the characteristics of high stability rate, and the TCM group showed obvious advantages in survival [9]. TCM treatment of cancer mainly includes acupuncture and drug treatment. Both methods take treatment with syndrome differentiation and eliminating pathogenic factors as the therapeutic principles, and achieve the effect of reconstructing the regulatory function of the body by regulating the function of qi, blood, yin and yang, and viscera of the body [10, 11]. However, most of the previous cancer research has been on drug therapy, and acupuncture has been lacking. In recent years, relevant clinical and experimental studies have shown that acupuncture plays a very important role in the rehabilitation of cancer patients by regulating qi and blood and promoting meridians. It can regulate the immune function of patients, play a role in relieving clinical symptoms, relieving pain syndrome, and reducing adverse reactions after chemotherapy [12, 13]. Existing clinical studies have shown that acupuncture combined with chemoradiotherapy can significantly reduce the immunosuppression caused by chemoradiotherapy, improve hematopoietic function, promote the increase of white blood cell count, improve the main symptoms and signs after chemotherapy, and significantly increase the total effective rate [14]. Therefore, acupuncture and moxibustion combined with comprehensive treatment can give full play to the advantages of various treatment methods, adjust the balance of the body's internal environment, and stimulate the body's various potential. In conclusion, acupuncture and moxibustion has a high application prospect in LC treatment, but there are not many related comprehensive application studies.

With the intellectualization of today's society, the application of artificial intelligence technology in clinical practice is more and more extensive, especially the emergence of medical robots provides more possibilities for clinical development [15]. At present, an intelligent acupuncture robot has been proposed by experts to assist clinical acupuncture treatment [16]. The intelligent acupuncture robot includes the function of automatic acupuncture, which will greatly reduce the working pressure of clinicians. In addition, in order to solve the problem that some patients are reluctant to perform acupuncture due to fear of pain, some experts have proposed a painless and infection-free laser acupuncture therapy [17]. The acupuncture treatment is designed and implemented on a smart phone by integrating a variety of machine learning algorithms and computer vision technology. The positioning error is less than 5 mm, convenient for patients to use, and has a good application effect.

Therefore, this work selected LC patients as research objects and combine automatic laser acupuncture therapy with comprehensive drugs to explore the effects of this therapy on patients' prognosis and side effects, so as to provide reference for the treatment of clinically related diseases.

Study Subjects

88 patients with LC who were treated in Affiliated Quanzhou First Hospital of Fujian Medical University from January 2020 to January 2021 were selected as the study subjects. The patients were randomly divided into two groups: EG and controls, with 44 patients in each group. Inclusion criteria: Pathological diagnosis of non-small cell lung cancer, clinical stage IIIB ~ IV; age range 18 ~ 75 years (including 18, 75 years); Karnofsky score ≥ 60 points, or behavioral status score PS0 ~ 2, expected survival time more than 4 months; lesions can be assessed and measured or distant lesions can be assessed and measured; blood routine, renal function was normal, no serious heart, liver, lung dysfunction. Exclusion criteria: Patients with brain metastasis and uncontrolled clinical symptoms; patients with mental illness unable to communicate with the investigator normally; patients with malignant pleural effusion; patients with active nodules or severe infection; patients with active recurrent cancer; white blood cells < 1 × 10⁹/L or neutrophils < 0.5 × 10⁹/L; patients with bleeding tendency or platelets < 30 × 10⁹/L. It obtained patient informed consent and complied with medical ethics requirements of Affiliated Quanzhou First Hospital of Fujian Medical University.

Laser Acupuncture Positioning System

Automatic positioning in laser acupuncture positioning system is divided into two steps. The first step is image-based acupoint location. The smartphone camera is used to locate facial acupoints. The camera reads the image first as input and passes it to the acupoint estimation process to obtain the coordinates of the acupoints in the image space. In order to improve the recognition speed and accuracy, experts should introduce the Mobilenet-based convolutional neural network (CNN) [18] technology to detect the area containing acupoints, and adopt the constrained local method (CLM) for landmark detection. The second step is hand-eye calibration. The obtained image coordinates are transferred to the coordinate transformation process to obtain the coordinates of the acupoints in the space of the robot arm. The calculated coordinates of the acupoint robotic arm are used for automatic laser acupuncture positioning of the robot arm. The research shows that the average acupoint positioning error of the smartphone-based laser acupuncture automatic acupoint positioning system is less than 5 mm, and the automatic laser acupuncture combined with lifting and thrust functions is compared with no lifting and thrust functions. It can significantly improve its effect on pulse amplitude and pulse rate variability. Research that can be used in this study.

Treatment Method

The EG was treated with acupuncture combined with integrated Chinese and western medicine, and controls were treated with integrated Chinese and western medicine. Specific details are as follows.

Patients in both groups were treated with traditional Chinese medicine and chemotherapy.

Chinese medicine treatment: (1) qi-stagnancy and blood stasis type: Taohong Siwu Decoction addition and subtraction, with elemene. (2) phlegm-stasis accumulation type: Ditan Decoction addition and subtraction, combined with 100 mL Kanglaite. (3) Yin deficiency and toxic heat type: Sha Shen Mai Dong Tang and five ingredients toxin-removing beverage, combined with Kang Ai Needle 40ml. (4) Deficiency of both qi and yin: Ginseng Yangrong Decoction, combined with 60mL Kang’ai injection. The application method of all drugs was intravenous drip once a day, 14 days as a course of treatment, and the interval between each course of treatment was 14 days, continuous treatment of 2 courses.

Chemotherapy regimen: First-line chemotherapy regimen: GP regimen: gemcitabine 1,250 mg/m² + cisplatin 75 mg/m², treatment cycle: 21 days. TP regimen: Taxol 135 mg/m² + cisplatin 75 mg/m², treatment cycle: 21 days. Second-line chemotherapy regimen: Docetaxel 75 mg/m² + cisplatin 75 mg/m², treatment cycle: 21 days. If serious AR occurred during the treatment, patients were given Chinese medicine for phlegm, detoxification, supplementing qi and nourishing yin, and patients were given western medicine for anti-inflammatory, relieving cough and asthma. Local radiation therapy was administered to patients with bone metastases and superior compartment syndrome.

The EG was treated with acupuncture based on the above, and the specific details were as follows: (1) Acupoints selection: main acupoints: Feishu, Zhongfu, Taiyuan, Fengmen, Xinshu, Dazong, Gaohuang, Chize, Danzhong, and dorsal tender points. Acupoints: Lieque, Neiguan, and Zusanli. Then, some can be added according to the actual symptoms of patients, and the symptoms treated at each acupoint are shown in Table 1 and Table 2.

Table 1

Symptom treatment corresponding to each acupoint
Symptoms	Acupoints
Chest tightness and pain	Neiguan (diarrhea)
Hemoptysis	Chize (diarrhea)
Bloody sputum	Fenglong, Chize (diarrhea)
Cough and wind sputum	Taiyuan, Lieque Fenglong, Feishu
Cough and back pain	Shenzhu: Kongzui (diarrhea), Kunlun (diarrhea)
Cough and asthma	Rugen, Shufu, Fenglong, Xuanji, Qihai, moxibustion Dantian, Chuanxi
Continuous cough	Feishu, Tiantu, Jinsuo, shenzhu
Cough and expectoration	Fenglong (diarrhea), Danzhong (tonifying)

Table 2

Treatment of chemotherapy-related symptoms corresponding to each acupoint
Symptoms	Acupoints
Epigastric pain	Taiyuan, Zusanli, yuji, Weishu, Shenshu
Regurgitation vomiting	Xiawan, Zusanli, Weishu, Zhongwan, Pishu
Anorexia	Shaoshang, Sanli, Ranggu, Geshu, Weishu, Dachangshu
Abdominal distention	Shaoshang, Sanli, Ququan, Kunlun, Shangqiu, Ranggu, Taibai, Xingjian, Taiyuan, Shenmen
Fatigue asthenia	Geshu
Insomnia	Taiyuan, Gongsun, Yinbai, Feishu, Yinling, Sanyinjiao
Diarrhoea	Taichong, Shenque, Sanyinjiao
Constipation	Chengshan, Taixi, Zhaohai, Taichong, Xiaochangshu, Taibai, Zhangmen, Pangguangshu
Numbness of hands and feet	Shousanli, Quchi, Waiguan, Hegu, Yangxi (hand), Weizhong, Huantiao, Yinlingquan, Yanglingquan, Taixi, Zhiyin (foot)

(2) Pulse-taking method: During pulse diagnosis, the patient was placed in supine position, the forearm was naturally extended anteriorly and placed at the same level as the heart, the palm was upward after the wrist was straightened, and the finger was slightly bent to extend the position of the cunkou of the hand, so as to ensure the patency of the local blood flow and facilitate pulse diagnosis. When the lower finger of the pulse was examined, the middle finger compressed the medial closing part of the high bone on the posterior side of the palm, the index finger was placed in the anterior cun pulse of the patient’s middle finger, and the ring finger was placed in the posterior chi pulse of the patient’s middle finger to keep the finger ends flat. Fingers were arched slightly and formed a 45° angle with the patient’s body surface, and the position was adjusted according to the patient’s body size, with those who were tall slightly distanced, while those who were short slightly closed. The thumb and index fingers of the Renying pulse were taken at the carotid pulse at the anterior border of the sternocleidomastoid muscle. (3) Acupuncture method: × 25 mm filiform needle was used. The principle of needle insertion: the needle was inserted quickly. The depth of needle insertion was 15 inches, and the needle retention time was half an hour. It was performed once or twice a day, a total of two courses; each course of ten days; the interval between courses: 7 days.

Outcome Measures

(1) Life function indexes of cancer patients: The QOL of cancer patients was observed and analyzed with the Life Function Index Scale of Cancer Patients, and the score was 0 ~ 7 points. The evaluation time was once before and after treatment.

(2) FLIT score scale: the assessment was carried out once before and after treatment.

(3) Symptom relief: LC patients were observed for cough, expectoration, sputum blood, chest pain, shortness of breath, fever symptoms and regurgitation vomiting, anorexia, fatigue, diarrhea, and numbness of hands and feet symptoms during chemotherapy. The scoring methods were no symptoms: 0-point, mild symptoms: 1-point, moderate symptoms: 2 points, and severe symptoms: 3 points. According to the decrease of TCM symptom score after treatment, the therapeutic effect was evaluated. It is considered that when the integral is reduced by ≥ 70%, it belongs to significant improvement; when the integral value is reduced by 30% ~ 70%, it belongs to partial improvement; when the integral value is unchanged or increased by ≤ 30%, it belongs to no improvement.

(4) Immune parameters: T lymphocyte subsets in serum were measured before and after treatment, including CD3+, CD4+, and CD8+. Efficacy was improved when T lymphocyte subsets levels increased abnormally by ≥ 10% or returned to normal levels after treatment. Efficacy was considered reduced if there was an abnormal decrease in the level of T lymphocyte subsets ≥ 10% after treatment or a shift from normal to abnormal. If the level of T lymphocyte subsets changed by less than 10% after treatment compared with that before treatment or remained in the normal range, it was considered that the efficacy did not change.

Statistical Methods

SPSS 22.0 statistical software was used for data analysis. Measurement data were expressed as mean ± standard deviation (\(\overline{\text{x}}\)±s). t test was used for comparison between groups. Analysis of variance was used for comparison within groups. χ² test was used. P < 0.05 was considered statistically significant.

Comparison of General Data

The results of the comparison of general data are shown in Table 3. It shows that the mean age of patients in the EG was 55.8 ± 11.3 years, and the mean age of controls was 53.9 ± 9.33 years. The EG consisted of 22 male patients and 22 female patients; controls consisted of 20 male patients and 24 female patients. There was no significant difference in the general data between the two groups (P > 0.05), with comparability.

Table 3

General data of patients
Item		EG (n = 44)	Controls (n = 44)	t	P
Age (years)		55.8 ± 11.3	53.9 ± 9.33	1.13	0.97
Gender				3.37	1.55
	Male	22	20
	Female	22	24
Site				2.21	3.17
	Center	17	19
	Periphery	27	25
Type				0.85	1.05
	Squamous cell carcinoma	11	13
	Adenocarcinoma	9	12
	Other	24	19
Staging				1.12	0.98
	III_B	18	20
	IV	26	24
PS score (ECOG)		1.87 ± 0.99	2.01 ± 1.12	0.93	1.12

Comparison of LC Symptom Improvement

The comparison results of LC symptom improvement are shown in Figs. 1 and 2. Figure 1 shows that before treatment, the LC symptom score of the EG was 17.3 ± 11.3, and the LC symptom score of controls was 16.8 ± 9.8, P > 0.05. After treatment, the LC symptom score of the EG was 6.88 ± 2.21, and the LC symptom score of controls was 10.2 ± 2.08 (P < 0.05).

Figure 2 indicates that the number of patients in the EG who were not significantly effective, effective, and ineffective in the treatment effect was 2, 33, and 9, respectively; the number of patients in the controls who were not significantly effective, effective, and ineffective in the treatment effect was 3, 20, and 21, respectively, P < 0.05.

Comparison Results of FLIT Score Scale

The comparison results of FLIT scoring scale were shown in Table 4. Table 4 show that the scores of all dimensions (good body and ability, good psychology, difficulty due to cancer, and nausea) in the EG and controls before treatment were 33.1 ± 11.3 VS 34.2 ± 10.9, 26.5 ± 8.77 VS 27.1 ± 8.06, 11.5 ± 3.31 VS 12.9 ± 3.09, 7.33 ± 2.88 VS 7.65 ± 2.08, and 6.09 ± 1.13 VS 6.11 ± 1.08, P > 0.05. After treatment, the scores of all dimensions in the EG and controls were 30.7 ± 11.2 VS 33.9 ± 10.07, 20.08 ± 4.33 VS 24.5 ± 5.11, 8.77 ± 3.31 VS 11.6 ± 2.88, 8.33 ± 3.36 VS 9.36 ± 4.08, 3.22 ± 1.18 VS 5.31 ± 1.27, P < 0.05.

Table 4

Comparison of FLIT scores between the two groups before and after treatment.
Dimensional	Experimental group (n = 44 cases)		Control group (n = 44 cases)
Dimensional	Before treatment	After treatment	Before treatment	After treatment
Good health and ability	33.1 ± 11.3	30.7 ± 11.2	34.2 ± 10.9	33.9 ± 10.07*
Psychological well-being	26.5 ± 8.77	20.08 ± 4.33	27.1 ± 8.06	24.5 ± 5.11*
Hard time with cancer	11.5 ± 3.31	8.77 ± 3.31	12.9 ± 3.09	11.6 ± 2.88*
Social good	7.33 ± 2.88	8.33 ± 3.36	7.65 ± 2.08	9.36 ± 4.08*
Nausea	6.09 ± 1.13	3.22 ± 1.18	6.11 ± 1.08	5.31 ± 1.27*
*Note "" after treatment compared with EG group, there was statistical significance P < 0.05.**

Comparison of Cellular Immunity

The comparison results of cellular immunity before and after treatment are shown in Figs. 3 and 4. Figure 3 shows that the comparison of CD3+, CD4+, and CD8 + measured values between the two groups before treatment was 50.8 ± 11.3 VS 51.3 ± 10.8, 34.9 ± 8.33 VS 33.8 ± 7.12, and 22.6 ± 6.33 VS 23.1 ± 5.08, P > 0.05. After treatment, the measured values of CD3+, CD4+, and CD8 + in the two groups were 56.08 ± 22.3 VS 52.9 ± 21.81, 35.2 ± 12.3 VS 31.3 ± 11.09, and 26.08 ± 7.74 VS 20.7 ± 8.35, respectively (P < 0.05).

Comparison of Traditional Chinese Medicine (TCM) Syndrome Scores before and after Treatment

The results of TCM syndrome scores before and after treatment are shown in Fig. 5. Figure 5 shows that TCM syndrome score was 30.1 ± 10.8 and 29.9 ± 9.98 in the EG and controls before treatment, P > 0.05. After treatment, the TCM syndrome score of the EG was 19.8 ± 6.06, and that of the controls was 23.6 ± 7.33, P < 0.05.

Comparison of Piper Fatigue Scale (PFS) Scores before and after Treatment

The results of the comparison of PFS scores before and after treatment are shown in Fig. 6. Before treatment, the PFS scores of patients in the EG and controls were 8.31 ± 2.01 and 8.08 ± 1.08, P > 0.05. After treatment, the PFS scores of patients in the EG and controls were 4.87 ± 2.01 and 7.11 ± 1.68, P < 0.05.

Nausea and Vomiting Grading Comparison

The comparison results of nausea and vomiting grading are shown in Table 5. The results showed that there was no significant difference in the number of patients with grade 0, I, II, III, and IV nausea and vomiting between the EG group and the control group before treatment (P > 0.05) (0 VS 0, 3 VS 5, 6 VS 7, 33 VS 31, and 2 VS 1, respectively). After treatment, the number of patients with grade 0, I, II, III, and IV nausea and vomiting in the EG group was significantly lower than that in the control group (P < 0.05) (20 VS 7, 18 VS 3, 3 VS 20, 2 VS 10, and 1 VS 4, respectively).

Table 5

Comparison of the severity of nausea and vomiting between EG and the control group before and after treatment.
Level	Experimental group (n = 44 cases)		Control group (n = 44 cases)
Level	Before treatment	After treatment	Before treatment	After treatment
Level 0	0	20	0	7*
Level I	3	18	5	3*
Level II	6	3	7	20*
Level III	33	2	31	10*
Level IV	2	1	1	4*
*Note "" after treatment compared with EG group, there was statistical significance P < 0.05.**

LC is one of the most common malignant tumors in clinical practice, and its morbidity and mortality rank first among malignant tumors [19]. 80% of LC types are non-small cell carcinomas. Clinical statistics show that more than 50% of patients reach advanced stages of cancer at the beginning of diagnosis and can’t be treated surgically [20, 21]. Therefore, the treatment of patients with advanced LC has always been the focus of clinical research. In recent years, the more concerned and popular treatment regimens are platinum-based third-generation chemotherapy regimens and targeted drugs [22]. These treatments seem to hold new promise for the treatment of LC. The short-term efficacy of patients seems to have improved under the above treatments, but the long-term efficacy remains very unsatisfactory [23]. In addition, the strong and serious toxic side effects brought about by these treatment regimens not only reduce the patient acceptance, but also greatly reduce the QOL of patients even if the treatment is successful [24]. Correspondingly, TCM treatment has shown significant advantages in cancer treatment. TCM has a long history of treating tumors, and is cheap with few side effects [25]. In recent years, it has been found that not only traditional Chinese medicine plays a good role in the treatment of cancer, but acupuncture also has important advantages. Relevant clinical studies have shown that TCM comprehensive therapy and comprehensive drug therapy of LC have better therapeutic effects [26]. However, clinical studies often neglect the adjuvant therapeutic effect of acupuncture [27]. In order to confirm the application effect of acupuncture and moxibustion combined with Western medicine in cancer, the study explored lung cancer patients.

The results showed that after treatment, the LC symptom of EG (6.88 ± 2.21) was significantly lower than that of the control group (10.2 ± 2.08) (P < 0.05). After treatment, the PFS score of EG (4.87 ± 2.01) was lower than that of the control group (7.11 ± 1.68), and the number of patients with no therapeutic effect in EG group (9 cases) was significantly lower than that of the control group (21 cases), showing P < 0.05. It is suggested that acupuncture and moxibustion can improve the function of comprehensive drug therapy. Studies have shown that acupuncture plays an irreplaceable and non-negligible role in cancer treatment, and its main effect is to relieve AR after chemotherapy [28]. Acupuncture and moxibustion has a bidirectional regulating effect, stimulating and inducing the body's regulatory system, restoring the normal function, and also playing a very important role in prolonging the survival time of patients. In addition, acupuncture has many advantages, such as safety, simplicity, and no side effects [29]. A previous study [30] had also demonstrated that acupuncture is a promising intervention, both post-operative and post-chemotherapy, as a beneficial alternative strategy to promote reported outcomes (PROs) in adult patients with lung cancer at all stages of application in patients with lung cancer. The other study found [31] that acupuncture treatment can alleviate limb weakness, numbness, limb end pain and other adverse reactions caused by ICI treatment in lung cancer patients. This work also found the number of grades 0, I, II, III, and IV nausea and vomiting patients in the EG group and the control group, and the results were 20 VS 7, 18 VS 3, 3 VS 20, 2 VS 10, and 1 VS 4, respectively, showing P < 0.05. These results indicate that acupuncture treatment can significantly improve the adverse reactions and severity of patients after chemotherapy. In order to follow the pace of intelligent development, the study used a smart phone based laser acupuncture automatic point positioning system. The above results show that acupuncture treatment with the aid of automatic point positioning system of laser acupuncture is effective, and also indirectly confirm that automatic point positioning system of laser acupuncture has certain application value. It is consistent with the research results of this research expert, which indicates that artificial intelligence technology has very important application value in the treatment of clinical diseases in the future and is worthy of further clinical exploration. In conclusion, acupuncture combined with drug therapy based on artificial intelligence has a good therapeutic effect, and the incidence of nausea, vomiting and other AR after chemotherapy is also lower, and the immunity of patients is also higher.

The work was concluded by exploring the therapeutic effect of acupuncture therapy based on AI combined with integrated Chinese and western medicine on lung cancer patients and the intervention effect of side effects after chemotherapy. The PFS score, TCM syndrome score, nausea and vomiting grade 0, grade I, grade II, grade III, and grade IV of EG were significantly different after treatment. In conclusion, acupuncture combined with integrated medicine has a high application value in the treatment of LC and the prevention of AR after chemotherapy. However, because there are some defects and shortcomings in sample size, it will expand the sample to further explore this problem.

Ethical Approval

Written informed consent was obtained from all participants

Competing interests

None.

Authors' contributions

All authors contributed to the conception and the main idea of the work. D.Z performed the experimental tests, G.C, and X.L analyzed the data. Y.Z supervised the work and provided comments and additional scientific information.

Funding

None.

Availability of data and materials

All are available upon a reasonable request.

G. M. Leyden, M. P. Greenwood, V. Gaborieau, et al., “Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation,” Br J Cancer, vol. 24, pp. 222, 2022.
L. Guo, M. E. Wright, M. C. Osias, et al., “Creation and Evaluation of the Illinois Cancer Risk Index as a Predictor of Four Common Cancers,” Prev Chronic Dis, vol. 9, pp. E75, 2022.
Z. Wang, S. Li, L. Wu, et al., “Effect of acupuncture on lung cancer-related fatigue: study protocol for a multi-center randomized controlled trial.,” Trials., vol.20,no.1,pp.625, 2019.
R. Kuang, G. Xiong, W. Lv, et al., “Efficacy and safety of acupuncture combined with analgesics on lung cancer pain: A protocol for systematic review and meta-analysis.,” Medicine (Baltimore). vol.100,no.23,pp.e26225, 2021.
J. M. Moran, L. M. Puerto-Parejo, O. Leal-Hernandez, et al., “Acupuncture for cancer-related fatigue in lung cancer patients:methodological and statistical issues.,”Support Care Cancer.,vol.27,no.1,pp.1-2, 2019.
M. D. Guerra-Martín, M. S. Tejedor-Bueno, M. Correa-Casado.,“Effectiveness of Complementary Therapies in Cancer Patients: A Systematic Review.”Int J Environ Res Public Health.,vol.18,no.3,pp.1017，2021.
G. Li, C. Zhang, C. Wang, et al., “Acupuncture against chronic postsurgical pain in non-small cell lung cancer patients: A protocol of randomized controlled trial.,” Medicine (Baltimore).,vol.100,no.40,pp.e27461, 2021.
W. T. Li, Y. H. Liu, P. Pan, et al., “Effects of "Tiaoyi Sanjiao" acupuncture and moxibustion on cancer-induced fatigue and immune function in patients with advanced non-small cell lung cancer,”Zhen Ci Yan Jiu.. vol.45,no.12,pp.1000-5. Chinese, ,2020.
Y. L. Wang, J. X. Li, X. Q. Guo, et al., “Effect of acupuncture in different time on nausea and vomiting induced by chemotherapy of lung cancer,” Zhongguo Zhen Jiu, vol.39,no.12,pp.1269-73, 2019. Chinese.
H. Yue, S. Zhou, H. Wu, et al., “Efficacy and safety of electro-acupuncture (EA) on insomnia in patients with lung cancer: study protocol of a randomized controlled trial.,”Trials,vol.21,no.1,pp.788, 2020.
Z. Fu, X. Zhang, X. Zhou, et al., “In vivo self-assembled small RNAs as a new generation of RNA itherapeutics,” Cell Res. vol.31,no.6,pp.631-648, 2021.
Q Liang, K Zhang, S Wang, et al., “Acupuncture for Cancer Pain - An Adjuvant Therapy for Cancer Pain Relief.,”Am J Chin Med.,vol.48,no.8,pp.1769-1786, 2020.
F. Kong, Z. Wang, D. Liao, et al., “Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. Front Oncol.,”no.11,pp.739191, 2021.
Z. Song, F. Yang, H. Du, et al., “Role of artemin in non-small cell lung cancer.,”Thorac Cancer., vol.9,no.5,pp.555-562, 2018.
B. Yang, X. J. Li, Y. Z. Hou, et al., “Non-invasive (non-contact) measurements of human thermal physiology signals and thermal comfort/discomfort poses-A review,” Energy and Buildings, vol. 224, pp. 110261, 2020.
T. W. Chan, C. Zhang, W. H. Ip, et al., “A Combined Deep Learning and Anatomical Inch Measurement Approach to Robotic Acupuncture Points Positioning,” Annu Int Conf IEEE Eng Med Biol Soc, vol. 2021, pp. 2597-2600. 2021.
K. C. Lan, C. Y. Lee, G. S, et al., “An Initial Study on Automated Acupoint Positioning for Laser Acupuncture,” Evid Based Complement Alternat Med. vol. 2022, pp. 8997051, 2022.
X. Zhou, Y. Li, and W. Liang, “CNN-RNN Based Intelligent Recommendation for Online Medical Pre-Diagnosis Support,” IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol. 18, no. 3, pp. 912-921, 2021.
T.D. Tailor, S. Bell, F. X. Doo, et al., “Repeat annual lung cancer screening after baseline screening amongst screen-negative individuals: No-cost coverage not enough,” J Am Coll Radiol, vol. 22 pp. 1546-1440, 2022.
K. Bae, E. Kim, J. S. Kong, et al., “Integrative cancer treatment may have a survival benefit in patients with lung cancer: A retrospective cohort study from an integrative cancer center in Korea.,”Medicine (Baltimore), vol.98,no.26,pp.e16048, 2019.
J. M. Cénat, E. Dromer, W. P. Darius, et al., “Incidence, factors, and disparities related to cancer among Black individuals in Canada: A scoping review,” Cancer, vol. 27, pp. 20-24, 2022.
S. Ritambhara, Tiwari, S. Vijayaraghavalu, M. A. Siddiqui, et al., “Clinical response of carboplatin-based chemotherapy and its association to genetic polymorphism in lung cancer patients from North India - A clinical pharmacogenomics study,” J Cancer Res Ther, vol. 18, no. 1, pp. 109-118, 2022.
N. Fukuda, N. Horita, S. Katakura, et al., “The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis,” Transl Lung Cancer Res, vol. 10, no. 8, pp. 3550-3566, 2021.
A. Gazeu, M. Aubert, D. Pissaloux, et al., “Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report,” Clin Lung Cancer, vol. 22, pp. S1525-7304, 2022.
Q. Zhao, H. Du, J. Liu, et al., “To Explore the Effects of Acupuncture and Medical Treatment at Different Times on the Gastrointestinal Reaction and White Blood Cell Count of Patients with Lung Cancer Chemotherapy.，”Appl Bionics Biomech.,pp.5261344, 2022.
L. G. Wu, D. N. Zhou, T. Wang, et al., “The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.,” Medicine (Baltimore). ,vol.100,no.12,pp.e25145, 2021.
L. Q. Wan, Y. Tan, M. Jiang, et al., “The prognostic impact of traditional Chinese medicine monomers on tumor-associated macrophages in non-small cell lung cancer.”Chin J Nat Med..,vol.17,no.10,pp.729-737, 2019.
Y. Zhang, X. Zhang, F. Wang, et al., “High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib.,”Open Med (Wars). vol.16,no.1,pp.1602-1607, 2021.
Y. G. Zhang, J. T. Niu, H. W. Wu, et al., “Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.,”Anal Cell Pathol (Amst).,pp.2021:6692811, 2021.
Z. Xi, X. Wei, Z. Ye, et al., “Acupuncture for adult lung cancer of patient-reported outcomes: A systematic review and meta-analysis,” Front Oncol, vol. 12, pp. 921151, 2022.
J. Li, D. Xu, Y. Liu, et al., “Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report,” Front Neurol, vol. 13, pp. 908282, 2022.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

The Curative Effect of Acupuncture Therapy Under Artificial Intelligence Combined with Integrated Chinese and Western Medicine for Lung Cancer Patients and The Intervention Effect of Side Effects After Chemotherapy

Status:

Version 1

Abstract

Figures

Introduction

Materials and Methods

Study Subjects

Laser Acupuncture Positioning System

Treatment Method

Outcome Measures

Statistical Methods

Results

Comparison of General Data

Comparison of LC Symptom Improvement

Comparison Results of FLIT Score Scale

Comparison of Cellular Immunity

Comparison of Traditional Chinese Medicine (TCM) Syndrome Scores before and after Treatment

Comparison of Piper Fatigue Scale (PFS) Scores before and after Treatment

Nausea and Vomiting Grading Comparison

Discussion

Conclusions

Declarations

References

Additional Declarations

Status:

Version 1